@foodnourish.bsky.socialđź“Ł New Podcast! "Retatrutide Weight Loss and Gray Market Risks" on @Spreaker #agonist #clinical #diabetes #dosage #glucagon #health #healthcare #incretin #medicine #metabolism #nutrition #obesity #peptide #pharmacovigilance #research #retatrutide #safety #sideeffects #trial #wellness
@metabologiajnl.bsky.social2026 #EASD/#EFSD Rising Star @AaronNovikoff brings to light novel strategies in anti-obesity #incretin pharmacology, redirecting focus away from poly-receptor agonism and towards the untapped potential of precision pharmacodynamics. #AntiObesity #Pharmacology link.springer.com/article/10.1...
@thelancetendo.bsky.social#Nutritional, #functional, and #psychological considerations for #incretin-based therapies in adults—an EASO, EFAD, and ECPO Consensus Statement www.thelancet.com/journals/lan...
#obesity
#GLP-1 receptor agonists
dual GLP-1–GIP receptor agonists
#FREE to read with registration (also FREE)
@biomedj.bsky.socialThe Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care.
#Incretin therapies reshape care, improving multiple obesity‑linked diseases and offering a practical framework for broader clinical use.
www.sciencedirect.com/science/arti... #OpenAccess #GLP1 #obesity #MedSky
@thelancetendo.bsky.social#Incretin hormones—glucagon-like peptide-1 (#GLP-1) and glucose-dependent insulinotropic peptide (#GIP)—act as a critical link connecting digestion, metabolism, and cardiovascular function, supporting physiological adaptations to nutrient intake www.thelancet.com/journals/lan...
#T2D #obesity
@thelancetendo.bsky.socialRobust trial evidence supports weight loss as a disease-modifying strategy in some conditions, including but not limited to type 2 #diabetes & #heartfailure with preserved ejection fraction www.thelancet.com/journals/lan...
#incretin-based therapies #weightloss #T2D
@lancetrh-europe.bsky.social#Incretin-based therapies have transformed #obesity treatment, but health systems have not kept pace
New @easoobesity.bsky.social position statement defines this paradox and proposes a model for integrating incretin-based therapies into comprehensive #ObesityCare